Abstract:V600E BRAF have been identified as new promising targets for the design of novel anticancer agents. It is reported that the inhibitors based on 2,3-dihydroimidazo[4,5]pyridin-2-one scaffold and a meta -substituted middle ring exhibit potent inhibitory activities toward V600E BRAF. To investigate how their chemical structures relate to the inhibitory activities and to identify the key structural elements that are required in the rational design of potential drug candidates of this class, molecular docking simulations and three-dimensional quantitative structure–activity relationship (3D-QSAR) methods were performed. The bioactive conformation was explored by docking one potent compound 1 into the active site of BRAF in its DFG-out inactive conformation. The constructed CoMFA and CoMSIA models produced statistically significant results with the cross-validated correlation coefficients q 2 of 0.563 and 0.624, non-cross-validated correlation coefficients r 2 of 0.982 and 0.962, and predicted correction coefficients r pred 2 of 0.822 and 0.875, respectively. In addition, the CoMFA and CoMSIA models were used to guide the design of a series of new inhibitors of this class with predicted excellent activities. Thus, these models may be used as an efficient tool to predict the inhibitory activities and to guide the future rational design of 2,3-dihydroimidazo[4,5]pyridin-2-one derivatives with a meta substitution pattern as BRAF inhibitors with potent activities.

2D-QSAR Study of Carbocyclic Derivates Neuraminidase Inhibitors

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.

Pharmacophore Modeling, 3D‐QSAR Studies, and In‐silico ADME Prediction of Pyrrolidine Derivatives As Neuraminidase Inhibitors

Three Dimensional Quantitative Structure-activity Relationship of Cyclohexene Neuraminidase Inhibitors

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico

Molecular Docking, 3d-Qsar Studies, And In Silico Adme Prediction Of P-Aminosalicylic Acid Derivatives As Neuraminidase Inhibitors

Design, synthesis, bioactivity, and DFT calculation of 2-thiazolyl-hydrazone derivatives as influenza neuraminidase inhibitors

Design, Synthesis, and Activity Study of Pyrrolidine Derivatives As Neuraminidase Inhibitors

QSAR Study of Carboxylic Acid Derivatives As HIV-1 Integrase Inhibitors

Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors

Neuraminidase Pharmacophore Model Derived from Diverse Classes of Inhibitors.

In Vitro Antiviral Effects and 3d Qsar Study of Resveratrol Derivatives As Potent Inhibitors of Influenza H1n1 Neuraminidase

Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors.

Novel Dual‐Site‐Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods

Design, synthesis and biological evaluation of sulfamethazine derivatives as potent neuraminidase inhibitors

Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors.

Pharmacophore Model and 3D-QSAR Study of Two Kinds of HCVNS3 Serine Protease Inhibitors

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Quantitative Structure_Activity Relationship Studies of Nevirapine Derivatives Anti-HIV Drug using New Three-dimensional Structure Descriptors

Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses.